Latest Breaking News On - Renal associates - Page 1 : comparemela.com

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress - Unicycive Therapeutics (NASDAQ:UNCY)

Study finds clinicians do not consistently use algorithms when dosing Mircera

LONG BEACH, Calif. — Clinicians do not consistently use algorithms for dosing methoxy polyethylene glycol-epoetin beta when treating patients with anemia, presented research shows. “Multiple dosing algorithms exist for the use of [methoxy polyethylene glycol-epoetin beta] MPG-EPO [Mircera, Vifor Pharma],” Namrata Shrestha, MD, of the University of the Incarnate Word, San

HEALWELL AI Participates in Leading-Edge Research on Chronic Kidney Disease Highlighting the Potential of its AI Powered Clinical Co-Pilot

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Execu

Ziltivekimab Improves Anemia Parameters in Patients With CKD

Together with previous research, this analysis suggests a new therapeutic approach for treating anemia in the CKD population. Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease (CKD).